OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
OKYO Pharma Limited has announced the grant of a significant European patent for OK-101 chemerin analogs, targeting the treatment of ocular inflammatory diseases and pain. This development strengthens the company’s intellectual property portfolio and underlines its commitment to innovating in the ocular therapy space. OKYO Pharma, which is actively pursuing strategic partnerships, has also recently demonstrated success in a Phase 2 trial for treating dry eye disease with OK-101.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
